Developed under the auspices of the University of Glasgow supported by unrestricted educational grants from Pfizer Italia S.r.l. and R-Pharm CJSC
The use of cytokine inhibitors as a treatment for inflammatory diseases is at the forefront of scientific development and is beginning to move from clinical trials into practice. With the approval of tofacitinib in many countries and other agents moving into phase II/III trials, staying current with the ongoing research is critical to clinical practice. The development of these agents brings in new targeted therapy and has the potential of great benefit to patients. This course outlines recent developments in cytokine signalling and IL-6 inhibition and show how these developments may come to clinical fruition over the coming years.
By following this programme, you will be able to:
Professor Leonard Calabrese
Director & Professor of Medicine,
Dr Leonard Calabrese is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Vice Chair of the Department of Rheumatic and Immunologic Diseases. Dr Calabrese is the Director of the RJ Fasenmyer Center for Clinical Immunology at the Cleveland Clinic specialising in diseases of the immune system, in particular, immunodeficiency diseases including HIV. Dr Calabrese has extensively published on the safety of biologic therapies for autoimmune diseases including the epidemiology of opportunistic and viral infections including PML. Dr Calabrese is also the Co-director of the Center for Vasculitis Care and Research and holds a joint appointment in the Department of Infectious Diseases.
Dr. Calabrese has lectured nationally and internationally on the subjects of clinical immunology, rheumatology and virology, and is the author of more than 400 published peer reviewed articles, book chapters and reviews.
|Cytokine Signalling Basic Science at EULAR 2015||
Professor Iain B. McInnes
Muirhead Professor of Medicine, Director of the Institute of Infection, Immunity and Inflammation,
Professor Iain McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA.
Professor McInnes’ research interests include understanding the role of cytokines in inflammatory synovitis. He leads a trials unit specialising in the use of biologic agents in early clinical trials in inflammatory arthritis. Professor McInnes has published widely in the areas of immunobiology and rheumatology, and he is Associate Editor of Annals of Rheumatic Diseases and a member of the executive Editorial Board of the European Journal of Immunology. His work, together with that of his colleagues at the University of Glasgow, has been widely recognised and has received many prizes and lectureships including the Michael Mason Prize 2001 from the British Society for Rheumatology, the Albrecht Hasinger Lectureship 2002, the Nana Svartz Lectureship 2008, and the Dunlop Dotteridge Lectureship for the Canadian Rheumatology Association in 2010. He gave the British Society of Rheumatology (BSR) Droitwich Lecture in 2012, and the Gerald Weissmann Lecture in Rheumatology in New York in 2013. A previous Chairman of The European League Against Rheumatism (EULAR) Scientific Committee, he is now Liaison Officer to the American College of Rheumatology for EULAR. He was elected a fellow of the Royal Society of Edinburgh in 2008, and in 2012 was elected as a Fellow of the Academy of Medical Sciences.
|Cytokine Signalling Clinical Science at EULAR 2015||
Professor Kevin Winthrop
Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology,
Professor Kevin Winthrop received his undergraduate degree in biology from Yale University and completed his MD degree at Oregon Health Sciences University in Portland, Oregon, USA. He obtained a masters degree in epidemiology at University California at Berkeley and completed an infectious disease epidemiology fellowship with the US Centers for Disease Control and Prevention (CDC) before serving as a staff member at CDC. He has co-authored more than 100 publications, many detailing epidemiologic and clinical aspects of infections and other adverse events associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies. Professor Winthrop also serves on the editorial board of Annals of Rheumatic Diseases, as Section Editor of Current Rheumatology Reports, and as an Associate Editor of BMC Infectious Diseases.
|IL-6 Basic Science at EULAR 2015||
Professor Douglas Veale
Principal Investigator at The Conway Institute for Biomedical and Biomolecular Research,
Douglas J. Veale is a Professor of Medicine, Director of Translational Research at DAMC, Consultant Rheumatologist at St Vincent’s University Hospital, and Fellow and Principal Investigator at The Conway Institute for Biomedical and Biomolecular Research, University College Dublin (UCD). He is a Fellow of both the Royal College of Physicians in Ireland (1997) and the Royal College of Physicians, London (1999). Professor Veale graduated from the Royal College of Surgeons in Ireland in 1984 and obtained his MD by thesis from UCD in 1992.
Professor Veale has established an international reputation in translational research in the areas of early arthritis, biopharmaceutical therapy, biomarkers and scleroderma. He has established an excellent research team including senior scientists, post-doctoral scientists, clinical research fellows and PhD students funded by peer-reviewed grants from The American Federation for Ageing Research, The European Union FP6 and an FP7 funded Innovative Medicines Initiative (IMI), The Health Research Board of Ireland, Science Foundation Ireland, the Programme for Research in Third Level Institutions and several industry partnership programmes.
Professor Veale’s primary research interests include inflammatory arthritis – rheumatoid/psoriatic arthritis, novel biopharmaceutical therapy and biomarkers.
|IL-6 Clinical Science at EULAR 2015||
Professor Ernest Choy
Director of the Cardiff Regional Experimental Arthritis Treatment and Evaluation (CREATE) Centre,
Professor Ernest Choy is Head of Rheumatology and Translational Research at the Institute of Infection and Immunity, and Director of the Cardiff Regional Experimental Arthritis Treatment and Evaluation (CREATE) Centre at Cardiff University School of Medicine, Cardiff, Wales, UK. He is also Honorary Consultant Rheumatologist at University Hospital of Wales, and Clinical Lead of the Welsh Arthritis Research Network (WARN). Previously, he was Reader and Director of the King’s Musculoskeletal Clinical Trials Unit in the Academic Department of Rheumatology, King’s College London. His major research interest is the treatment of rheumatic diseases focusing on the efficacy of new treatment strategies. He was Director of Research and Development at King's College Hospital between 2003 and 2008.
Professor Choy is a member of the European League Against Rheumatism (EULAR) Committee Standing Committee for International Clinical Studies Including Therapeutic Trials. He chairs the EULAR Taskforce on developing recommendations for management and classification criteria for fibromyalgia. Professor Choy has served as clinical expert to the National Institute for Clinical Excellence in the UK, and many pharmaceutical companies. He has published widely on treatments for rheumatic diseases in major medical journals such as
Date of preparation: July 2015